Vaishali Pharma Limited (VAISHALI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vaishali Pharma Limited (VAISHALI) has a cash flow conversion efficiency ratio of 0.030x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs20.46 Million ≈ $221.23K USD) by net assets (Rs673.82 Million ≈ $7.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Vaishali Pharma Limited for the company's overall valuation and market capitalisation.
Vaishali Pharma Limited - Cash Flow Conversion Efficiency Trend (2013–2026)
This chart illustrates how Vaishali Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vaishali Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaishali Pharma Limited ranked by their cash flow conversion efficiency. Explore earnings quality score of Vaishali Pharma Limited to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cannabist Company Holdings Inc
NEO:CBST
|
0.161x |
|
Gratifii Ltd
AU:GTI
|
0.129x |
|
Gaming Corps AB
ST:GCOR
|
0.791x |
|
Wizz Air Holdings PLC
LSE:WIZZ
|
0.897x |
|
ICH Co Ltd
KQ:368600
|
-0.014x |
|
Active Biotech AB
ST:ACTI
|
-0.169x |
|
Putprop Ltd
JSE:PPR
|
0.025x |
|
Sri Adhikari Brothers Television Network Limited
NSE:SABTNL
|
-36.713x |
Annual Cash Flow Conversion Efficiency for Vaishali Pharma Limited (2013–2026)
The table below shows the annual cash flow conversion efficiency of Vaishali Pharma Limited from 2013 to 2026. View Vaishali Pharma Limited share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs691.15 Million ≈ $7.47 Million |
Rs4.36 Million ≈ $47.12K |
0.006x | +102.27% |
| 2025-03-31 | Rs649.16 Million ≈ $7.02 Million |
Rs-180.38 Million ≈ $-1.95 Million |
-0.278x | -1575.62% |
| 2024-03-31 | Rs428.39 Million ≈ $4.63 Million |
Rs8.07 Million ≈ $87.24K |
0.019x | -29.31% |
| 2023-03-31 | Rs405.31 Million ≈ $4.38 Million |
Rs10.80 Million ≈ $116.77K |
0.027x | -46.76% |
| 2022-03-31 | Rs263.54 Million ≈ $2.85 Million |
Rs13.19 Million ≈ $142.60K |
0.050x | -44.23% |
| 2021-03-31 | Rs224.19 Million ≈ $2.42 Million |
Rs20.11 Million ≈ $217.49K |
0.090x | -40.41% |
| 2020-03-31 | Rs213.81 Million ≈ $2.31 Million |
Rs32.19 Million ≈ $348.11K |
0.151x | +13.11% |
| 2019-03-31 | Rs213.99 Million ≈ $2.31 Million |
Rs28.48 Million ≈ $308.01K |
0.133x | +128.99% |
| 2018-03-31 | Rs206.02 Million ≈ $2.23 Million |
Rs-94.60 Million ≈ $-1.02 Million |
-0.459x | -308.54% |
| 2017-03-31 | Rs38.69 Million ≈ $418.36K |
Rs8.52 Million ≈ $92.12K |
0.220x | -84.38% |
| 2016-03-31 | Rs32.54 Million ≈ $351.88K |
Rs45.88 Million ≈ $496.16K |
1.410x | +222.75% |
| 2015-03-31 | Rs32.35 Million ≈ $349.85K |
Rs-37.16 Million ≈ $-401.89K |
-1.149x | +49.84% |
| 2014-03-31 | Rs30.74 Million ≈ $332.40K |
Rs-70.40 Million ≈ $-761.32K |
-2.290x | -267.26% |
| 2013-03-31 | Rs27.73 Million ≈ $299.89K |
Rs37.97 Million ≈ $410.64K |
1.369x | -- |
About Vaishali Pharma Limited
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-vir… Read more